Xcout IntelNeuphoria Therapeutics Inc. competitors & alternatives
The 12 closest competitors and alternatives to Neuphoria Therapeutics Inc. among biotech companies — ranked by similarity to what Neuphoria Therapeutics Inc. actually does, not by market-cap band.
Subscribe to see Neuphoria Therapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.
Neuphoria Therapeutics Inc. at a glance
Neuphoria Therapeutics Inc. is a biotech company headquartered in Burlington, United States. It is publicly listed (NEUP) with a market capitalisation of $21.2M. Xcout tracks 16 named people at Neuphoria Therapeutics Inc., including Spyridon Papapetropoulos (Interim CEO & Executive Director).
Neuphoria Therapeutics Inc. leadership
- Spyridon PapapetropoulosInterim CEO & Executive Director
- Spyros PapapetropoulosPresident & CEO
- Timothy CunninghamFractional CFO
- Tim CunninghamChief Financial Officer
- Elizabeth DoolinSenior Vice President of Clinical Development
- Julie KernerSenior Vice President of Business Operations
10 more named people on record for Neuphoria Therapeutics Inc., with roles, board committees and tenure — see the full roster →
Recent Neuphoria Therapeutics Inc. news
2 corporate events on record, with sources — see the full timeline →
Top 12 Neuphoria Therapeutics Inc. competitors
Ranked by semantic similarity — how close each company is to Neuphoria Therapeutics Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Biotechnology
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Similar biotech company
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Biotechnology
Delix Therapeutics is a privately held biopharmaceutical company headquartered in Boston, Massachusetts, focused on transforming the treatment of brain health through neuroscience.
Biotechnology
Neurogastrx, Inc. is a pharmaceutical manufacturing company founded in 2012. Its main headquarters is located at 500 Unicorn Park Drive in Woburn, Massachusetts, where it is passionate about developing therapies to advance treatment.
Biotechnology
Myrobalan Therapeutics is a pre-clinical biotechnology company headquartered in Medford, Massachusetts, focused on developing oral small molecule therapies for central nervous system and neurodegenerative diseases. The company targets novel mechanisms to create neurorestorative treatments for CNS disorders.
Biotechnology
Neurona Therapeutics Inc. is a biotherapeutics company that focuses on developing cell-based therapies to address neurological disorders.
Biotechnology
Neurasic Therapeutics is a biotechnology company headquartered in Montreal, Canada, created to advance groundbreaking research into novel therapeutics.
Biotechnology
Delphia Therapeutics is a biotechnology research company headquartered in Cambridge, Massachusetts, with a team of 11 to 50 employees focused on therapeutic innovations.
Similar biotech company
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Life Sciences (Therapeutics)
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Biotechnology
Evecxia, Inc. is a holding and therapeutics company founded in 2013 and based in North Carolina, focusing on drug pipelines, patents, and clinical trials for neuropsychiatric conditions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Neuphoria Therapeutics Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Neuphoria Therapeutics Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →